The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy
Authors' conclusion
For people with tophaceous gout treated with allopurinol using a treat-to-target serum urate approach, improvements in TIQ-20 occurred, as did improvements in physical and imaging tophus measures.
Study context
- Population
- Participants with tophaceous gout in a 2-year clinical trial of allopurinol dose escalation using a treat-to-target serum urate approach39 with dual-energy CT (DECT) data
- Participants
- 58 participants
- Primary endpoint
- Change in TIQ-20 scores during urate-lowering therapy
- Follow-up
- 2 years
Methodological detailstreat-to-target serum urate approach, mixed-model repeated measures, DECT substudy
- Treat-to-target serum urate approach
- Mixed-model repeated measures
- DECT substudy
Primary result
As reported in the abstract
TIQ-20 score
- Mean (SD) TIQ-20 score at baseline
- 3.59 (1.77)
- Mean (SD) TIQ-20 score at 2 years
- 2.46 (1.73)
- Reduction over 2 years, P
- P < 0.0001
- Mean (95% CI) TIQ-20 change over 2 years
- −1.13 (−1.54, −0.71)
Further findings
Effect size (Cohen's d) for change over 2 years
- Sum of index tophi diameter
- 0.68
- DECT urate volume
- 0.50
- TIQ-20
- 0.71
All tophus measures · 2 years
- Improvements observed in all tophus measures over the 2-year period
Original publication
The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy. Rheumatology (Oxford). Published 9 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →